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Recent discovery of induced pluripotent stem cells (iPSCs)
open the great possibility to use patient own tissue to the
previously incurable diseases. Multipotent adult stem/pro-
genitor cells have been identiﬁed in nearly all human organs.
T h e s ec e l l sa r ee x p a n d e din vitro and are possible to be used
for personalized cell therapy. This special issue collected the
articles which discussed recent progresses in this ﬁeld.
Our body has self-defense systems to recover from dam-
ages. However, once tissues are damaged extensively, dam-
aged tissues cannot be recovered. These include hepatic (C.
H. Chiang, M. A. Puglisi), kidney, lung, and heart failures.
AlsoinneurodegenerativediseasesincludingParkinson’sdis-
ease, Alzheimer diseases, and ALS, patient cells are diﬃcult
to recover (H. Y. Ha). External stimuli such as high dose
of irradiation caused by cancer treatment (B. Phulpin) will
induce irreversible damages. There exist genetic disorders for
which there is no cure including progressive muscular dys-
trophies (E. Zucconi), cystic ﬁbrosis (V. Paracchini). Further
age-related dysfunctions are diﬃcult to be recovered. One
example is articular cartilage (S. Seo). Currently transplan-
tation has been shown to be an eﬀective treatment for these
tissue failures. However, transplantation has serious prob-
lems: shortage of organs to be transplanted and immune
rejection caused by great heterogeneity of human HLA.
Recent progresses of biotechnology open a new hope to treat
incurable diseases by using patient own tissues. This special
issue aimed to gather scientiﬁc papers about recent pro-
gresses in this ﬁeld.
iPSCs are novel stem cell populations induced from
mouse and human adult somatic cells through reprogram-
ming by transduction of deﬁned transcription factors. These
cells open the great possibility to personalized cell therapy
to treat incurable diseases (K. Seiler, T. Kunkanjanawan, H.
Y. Ha). Compared to ES cells, iPSCs are not rejected by host
immune cells theoretically. At least iPS cells are not rejected
once these cells are diﬀerentiated (C. H. Chiang).
Mesenchymal stromal cells (MSCs) from various sources
including bone marrow (S. W. Gendebien), adipose tissue
(W. Lattanzi), dental pulp, placenta, umbilical cord (E.
Zucconi, S. Park), menstrual blood (M. C. Rodrigues) and
amniotic mesenchymal stromal cells (V. Paracchini) have
been studied extensively by animal models.
Tissue stem cells are also used for personalized stem cell
therapy. Muscle-derived stem cells for bone formation (X.
Li), blood vessel-derived stem cells regenerate myoﬁbers in
injured and dystrophic skeletal muscles as well as improve
cardiac function after myocardial infarction (C. W. Chen).
Olfactory ensheathing cells (OECs) into nerve or spinal cord
injuries can promote axonal regeneration and remyelination
and restore functional recovery (C. Radtke). Some stem-
like cells reside in the transition area between the peripheral
corneal endothelium (CE) and the anterior nonﬁltering
portion of the trabecular meshwork (TM) replacing the lost
C E( W .Y .Y u ) .
Cell culture on scaﬀold enhances cell growth and dif-
ferentiation. Hydroxyapatite (HA) coating of (PCL/PVA)
nanoﬁbers enhances bone repair (E. Prosecka).
There are a number of reports for limitations of current
technologies that hinder iPSCs into practical use. Immuno-
genicity to syngeneic mice and tumor formation are re-
ported. MSCs also might promote tumor growth. MSCs2 Journal of Biomedicine and Biotechnology
immunomodulatory properties aﬀect greatly the host. More
works are sure to be needed to overcome these problems.
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